Herpes simplex virus (HSV) isolates were characterized from 8 AIDS patients in whom acyclovir and foscarnet therapy sequentially failed. The 6 postacyclovir (prefoscarnet) HSV isolates were resistant to acyclovir and susceptible to foscarnet. Of the 9 postfoscarnet isolates, 8 were foscarnet-resistant and acyclovir-susceptible, 1 was resistant to both drugs. Acycloviror foscarnet-resistant isolates retained susceptibility to cidofovir. The acyclovir-resistant isolates contained single-base substitutions or frameshift mutations in G or C homopolymer nucleotide repeats of the thymidine kinase gene. In contrast, the foscarnet-resistant strains contained single-base substitutions in conserved (II, III, or VI) or, more rarely, nonconserved (between I and VII) regions of the DNA polymerase (pol) gene. The single isolate exhibiting resistance to acyclovir and foscarnet contained mutations in both genes. In this study of clinical HSV isolates, DNA pol mutations conferring foscarnet resistance were not associated with decreased acyclovir or cidofovir susceptibility.
munodeficiency virus-infected subjects in whom acyclovir therapy had previously failed. In addition, the effects of various DNA pol mutations on acyclovir and cidofovir (a nucleotide analogue) susceptibility levels were determined.
Materials and Methods
Patients and isolates. Fifteen HSV isolates from 8 AIDS patients were provided by Sharon Safrin (University of California, San Francisco). The clinical histories of 6 of these patients (CD4 cell counts, 3-20/mm 3 ) have been reported [12] . In brief, these patients originally received acyclovir therapy and subsequently developed unresponsive HSV infections. Patients then received 1-5 courses of foscarnet, which preceded foscarnet-resistant infection by 2-12 months. At this stage, foscarnet-resistant lesions were healed in 3 of the 6 subjects after therapy was switched back to acyclovir (with or without foscarnet). The reversion to the acyclovir-susceptible phenotype occurred 2-5 months after withdrawal of acyclovir. Six of the 15 isolates were obtained at the time acyclovir treatment failed (prefoscarnet therapy) and the other 9 at foscarnet failure (postfoscarnet therapy).
Antiviral susceptibility assays. Susceptibilities to acyclovir, foscarnet, and cidofovir were determined by plaque reduction assay [12] . Acyclovir resistance was defined by 50% inhibitory drug concentration (IC 50 ) values у2 mg/mL [12] . Foscarnet resistance was defined by an IC 50 у100 mg/mL [12] or by a 3-fold increase in IC 50 values compared with those for pretherapy isolates from the same patients (when available) or with mean IC 50 values for wild type strains from immunocompetent subjects.
Genotypic analysis. The coding strand of the viral TK gene (1.2 kb) was amplified and sequenced, as reported elsewhere [3] . The conserved regions of the DNA pol gene (1.7 kb) were amplified with type-consensus primer: 5 -CGGATCCTGCGACCTCCCCG-3 (forward) and 5 -CGTCGTAAAACAGCAGGTCG-3 (reverse) by use of polymerase chain reaction (PCR) conditions similar to those used for the TK gene. PCR products were directly sequenced by use of a cycle sequencing kit (Taq DyeDeoxy Terminator; Applied Biosystems, Foster City, CA) and an automated DNA sequencing system (ABI 373A; Applied Biosystems). DNA pol and TK sequences of resistant isolates were compared with susceptible isolates (when possible) and reference strains available in GenBank.
Results
Phenotypic results. Acyclovir, foscarnet, and cidofovir susceptibility results for the 15 viral isolates from the 8 AIDS patients and for 10 wild type isolates from untreated immunocompetent subjects and 2 control strains (MS2 and KOS) are shown in table 1. In the first 4 patients with sequential isolates (pre-and postfoscarnet therapy), acyclovir IC 50 results decreased by a mean of 40.7-fold (range, 9.0-to 81.0-fold), whereas foscarnet IC 50 results increased by a mean of 4.5-fold (range, 3.1-to 7.6-fold). Comparison of pre-and postfoscarnet isolates of patient 5 revealed a 3.9-fold increase over time in foscarnet IC 50 results associated with a persistent acyclovirresistant phenotype. Two patients (6 and 7) for whom only postfoscarnet isolates were available also exhibited foscarnet resistance and a wild type acyclovir phenotype. Patient 8 had only a prefoscarnet therapy isolate available. This isolate was susceptible to foscarnet and resistant to acyclovir. Mean cidofovir IC 50 results for the 3 HSV-1 postfoscarnet isolates (1.9 mg/mL), the 6 HSV-2 prefoscarnet isolates (13.8 mg/mL), and the 6 HSV-2 postfoscarnet isolates (14.6 mg/mL) did not differ from those obtained by use of 5 HSV-1 (3.4 mg/mL) and 5 HSV-2 (18.1 mg/mL) wild type isolates from immunocompetent subjects.
Genotypic results. Table 1 summarizes HSV TK and DNA pol mutations found in the 15 HSV clinical strains. TK gene mutations were found in HSV-2 prefoscarnet therapy isolates from patients 1-5 and 8 (no prefoscarnet isolates were available for patients 6 and 7). By comparison with susceptible isolates and reference strains, acyclovir-resistant isolates from 3 patients (1, 2, and 4) had an insertion of 1 G in a string of G's (nucleotide [nt] 433-439). The paired strains (pre-and postfoscarnet) of patient 5 contained a deletion of 1 C in a stretch of C's (nt 463-467). Two TK mutations were found in the acyclovir-resistant isolate of patient 3: a single-base substitution at nt 373 (GrA) and a deleted C in a string of C-s (nt 551-556). These additions or deletions led to the formation of a stop codon 28-82 amino acid (aa) downstream. Finally, the isolate of patient 8 had a sequence of 3 G's substituted by 3 C's (nt 175-177) that resulted in a GlyrSer change at aa 59.
HSV-2 postfoscarnet therapy isolates from patients 1-6 contained a single-base substitution within the viral DNA pol gene, after comparison with pretherapy isolates from the same patients (when available) and reference strains ( figure 1) . Specifically, we found unique mutations at aa 724, 729, 783, 785, Figure 1 . Diagram of herpes simplex virus (HSV)-1 and -2 DNA polymerase mutations conferring resistance to different antivirals (ACV, acyclovir; FOS, foscarnet; PAA, phosphonoacetic; APH, aphidicolin) from this study and previous studies [5] [6] [7] [8] [9] [10] [11] . Conserved regions are indicated by amino acid no. a, Clinical isolates. Matthews et al. [6] found phosphonoacetic acid hypersensitivity for mutation 724 (b). Note that resistant strains containing reported mutations were not necessarily tested for all antivirals listed above.
850, and 912. The 3 HSV-1 postfoscarnet strains from patient 7 contained dual mutations in the DNA pol gene, at aa 724 and 920.
Discussion
Herpesviridae DNA pols share 8 regions of high homology, identified as conserved regions I-VII and A [11] . Our study showed that single-base substitutions, located mainly in the conserved regions of the viral DNA pol gene, are associated with a foscarnet-resistant phenotype in AIDS patients treated with this drug (figure 1). Although most of our patients had previously shed acyclovir-resistant HSV isolates containing substitutions or frameshift mutations in the viral TK gene, only 1 isolate was resistant to both foscarnet and acyclovir. In addition to a DNA pol mutation, this isolate contained a TK mutation also found in the prefoscarnet therapy isolate.
We found an AlarThr change at aa 724 (region II) of the postfoscarnet HSV-2 isolate from patient 2. The same mutation, associated with phosphonoacetic acid resistance, has been reported at analogous aa 719 in a laboratory-derived HSV-1 strain [5] . In contrast to our isolate, the latter mutant also displayed resistance to acyclovir. The postfoscarnet HSV-2 isolate of patient 3 contained an SerrAsn change at codon 729 (region II) that is analogous to the mutation found at aa 724 in all 3 HSV-1 foscarnet-resistant strains of patient 7. The latter isolates also contained a change at aa 920, a proline residue located between conserved regions I and VII. Gibbs et al. [8] and Larder et al. [5] both reported an acyclovir-resistant/ phosphonoacetic acid-resistant phenotype associated with the mutation at aa 724 in laboratory-derived HSV-1 mutants, whereas Matthews et al. [6] reported an acyclovir-resistant/ phosphonoacetic acid-hypersusceptible phenotype after they expressed the same DNA pol mutant in Saccharomyces cerevisiae. Nevertheless, our phenotypic results associated with mutations in conserved region II are consistent with those reported for cytomegalovirus (CMV) DNA pol mutants. Indeed, CMV mutations at positions 700 and 715 confer resistance to foscarnet but susceptibility to the guanosine analogue ganciclovir [13] . Our study and previous results highlight the fundamental role played by conserved region II in pyrophosphate analogue resistance [5, 13] and suggest that aa 724 and 729 (HSV-2) and their HSV-1 counterparts (aa 719 and 724) might play an important role in pyrophosphate binding [5] . In that context, the second mutation in patient 7, at aa 920, probably plays a minor role in foscarnet resistance.
We found 2 mutations conferring foscarnet resistance and acyclovir susceptibility in conserved region VI of the HSV-2 DNA pol gene: a LeurMet mutation in patient 1, at position 783 and an AsprAsn mutation in patient 4, at position 785. To date, no HSV mutations associated with antiviral resistance have been reported in that region. However, a mutation associated with foscarnet and ganciclovir resistance has been identified in region VI (codon 781) of the CMV DNA pol [14] . In addition to the 781 DNA pol mutation, this CMV mutant also contained mutations in the viral UL97 gene. Since no marker transfer have been performed, the role of the 781 DNA pol mutation in conferring resistance to nucleoside analogues is uncertain.
In patient 6, a single LeurIso mutation at position 850 of HSV-2 DNA pol region III was associated with a resistant foscarnet phenotype. Mutations in laboratory-derived (aa 841 and 842) [5, 8] and clinical (aa 841) [10] HSV-1 strains located near mutation 850 were associated with phosphonoacetic acid and acyclovir resistance. This proximity reinforces the possibility that mutation 850 in patient 6 is implicated in foscarnet resistance, although no pretherapy isolate was available for comparison. The postfoscarnet isolate of patient 5 contained an AsprVal mutation at position 912, between conserved regions I and VII. Both isolates (before and during foscarnet JID 1999; 180 (August) therapy) from this patient also exhibited acyclovir resistance and contained a TK deletion (see below).
All acyclovir-resistant HSV isolates from our study contained TK mutations, mainly nucleotide additions and deletions that have been well described [3, 4] . These mutations cause a frameshift in the coding sequence, presumably resulting in the formation of a truncated protein. In 3 HSV-2 isolates, we found an insertion of a G in a string of Gs (nt 433-439). That insertion was previously identified by our group as the predominant mutation in acyclovir-resistant clinical HSV-2 isolates [3] . We also found 2 different C deletions in patients 3 (nt 551-556 of prefoscarnet HSV-2 isolate) and 5 (nt 463-467 of both pre-and postfoscarnet HSV-2 isolates). Despite a mutation in the DNA pol gene, the acyclovir-resistant phenotype found in the postfoscarnet isolate of patient 5 is most likely due to the TK mutation. However, transfection experiments need to be done to determine whether the DNA pol mutation has any additive effect on acyclovir resistance. The acyclovir-resistant isolate of patient 3 also contained an AlarThr change at aa 125 (outside any known active domains of the TK gene). The relevance of this mutation is unclear considering the simultaneous presence of a frameshift mutation. Finally, we found an unreported change of 3 Gs for 3 Cs at aa 59 (GlyrPro) within the proposed ATP-binding site in the acyclovir-resistant isolate of patient 8.
Susceptibility testing for the nucleotide analogue cidofovir did not reveal a particular pattern associated with foscarnet or acyclovir resistance. Nevertheless, we found that wild type HSV-1 isolates were, in general, more susceptible to cidofovir than were HSV-2 isolates, which may complicate the interpretation of our data. In CMV, mutations in conserved region IV and between regions IV and A are associated with dual resistance to cidofovir and ganciclovir but susceptibility to foscarnet [15] . In our study no mutations were found within these regions.
In conclusion, we found DNA pol mutations in foscarnetresistant isolates after foscarnet therapy in persons who had previously developed acyclovir-resistant HSV infections. In our study, HSV DNA pol mutations in conserved regions II, III, and VI were associated with resistance to foscarnet but susceptibility to acyclovir and cidofovir, which is mostly consistent with CMV susceptibility patterns. The relevance of most of our DNA pol mutations in conferring foscarnet resistance is based on their absence in isolates before therapy and on their location in conserved regions of the gene. However, confirmatory transfection experiments are necessary to exclude the effects of other DNA pol mutations located outside the conserved regions and to resolve the issue concerning the resulting acyclovir phenotype. Finally, our results also provide some useful information about phenotypic variations in HSV isolates over time. In particular, the reversion to the acyclovir-susceptible phenotype in most HSV isolates seems to indicate that TK-deficient mutants are unlikely to reactivate from latency. On the other hand, partially healed HSV lesions still may contain a subpopulation of acyclovir-resistant viruses that could reemerge on reinstitution of acyclovir therapy.
